

Vol. 23, Suppl 3, April 2000

- 1 Status of Topotecan in Small-Cell Lung Cancer**
Drings, P. (Heidelberg); Stahel, R. (Zürich)

- 2 Phase I and II Evaluation of Novel Anticancer Agents: Are Response and Toxicity the Right Endpoints?**
Eisenhauer, E.A. (Kingston)

- 7 Topotecan/Taxol in First-Line Small-Cell Lung Cancer: Where is the Benefit?**
Tweedy Jr., C.R.; Andrews III, D.F. (Columbus, GA)

- 9 Topotecan in Second-Line Therapy of SCLC: Impact on Survival?**
Huber, R.M. (München); Gatzemeier, U. (Großhansdorf); Gosse, H. (Leipzig); von Pawel, J. (Gauting);
Hruska, D. (Gerlingen); Mezger, J. (Karlsruhe); Saal, J.G. (Flensburg); Kleinschmidt, R. (Bonn);
Steppert, C. (Ebensfeld); Steppeling, H. (Münster) for the SOABB Study Group

- 13 Topotecan in the First-Line Treatment of Small-Cell Lung Cancer**
Wolf, M. (Marburg)

- 18 Concluding Remarks**
Drings, P. (Heidelberg)

- II Imprint**

- U3 Guidelines for Authors**